StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.61+0.01 (+0.63%)

Close on Nov 18, 2026Market cap $80.25MP/E –Yield –

Polaryx Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Polaryx Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$8.02M. For fiscal 2025 it was -$3.94M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.94M–
FY2024Dec 31, 2024-$2.57M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.10M–
Q2 FY2026Jun 30, 2026-$1.37M–
Q1 FY2026Mar 31, 2026-$2.06M–
Q4 FY2025Dec 31, 2025-$1.49M–
Q3 FY2025Sep 30, 2025-$887.00K–
Q2 FY2025Jun 30, 2025-$858.00K–
Q1 FY2025Mar 31, 2025-$709.00K–

More Polaryx Therapeutics figures

See a number that looks wrong?